|| Checking for direct PDF access through Ovid
There are now a selection of broad-spectrum quinolones available which are likely to be used as first-line agents against community-acquired pneumonia. These agents have extended spectra of antibacterial activity compared with the earlier quinolones such as ciprofloxacin and ofloxacin. Compared with ciprofloxacin, these agents have increased activity against Gram-positive, anaerobic and atypical organisms. However, at present only trovafloxacin appears to be as effective as ciprofloxacin against Pseudomonas aeruginosa.Although generally well tolerated, the quinolones can cause some serious adverse effects and the adverse effect profiles of these newer quinolones are not identical. Despite the fact that all quinolones can cause photo-sensitivity reactions, this reaction is more frequent with sparfloxacin than with the other currently available agents.All of the newer quinolones are effective against a wide range of organisms and will need to be used with care in an attempt to minimise the emergence of resistance to these agents.